Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

BACKGROUND: Recently, modification of T cells with CAR has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a scFv. Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassani, Mahmoud, Hajari Taheri, Fatemeh, Sharifzadeh, Zahra, Arashkia, Arash, Hadjati, Jamshid, van Weerden, Wytske M., Abdoli, Shahriyar, Modarressi, Mohammad Hossein, Abolhassani, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute of Iran 2020
Materias:
Full Length
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984713/
https://www.ncbi.nlm.nih.gov/pubmed/31677604
http://dx.doi.org/10.29252/ibj.24.2.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984713/
https://www.ncbi.nlm.nih.gov/pubmed/31677604
http://dx.doi.org/10.29252/ibj.24.2.81

Ejemplares similares